for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover PharmAsia News
  [1 followers]  Follow
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [16 journals]
  • Korea Reimburses Gilead's Sovaldi, Harvoni To Aid Access
    • Abstract: With China and Japan moving to cut prices of Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni, South Korea has decided to reimburse the products from May. Although not all HCV genotypes will be covered by national health insurance, the move will sharply ease local patients' cost burden amid an outbreak of infections last year.
      PubDate: Thu, 28 Apr 2016 21:00:04 -040
  • Chugai Makes Regenerative Meds Move In Attractive Japan Environment
    • Abstract: Chugai is taking concrete steps into the burgeoning regenerative medicine sector in Japan through a new clinical and commercial alliance with a domestic venture for a therapy for knee cartilage disorders.
      PubDate: Thu, 28 Apr 2016 20:35:01 -040
  • INTERVIEW: A Revolution At GSK India
    • Abstract: Brace for GSK India's new avatar. The British multinational is revamping its business model in India and donning a new approach to create, deliver and capture value via a "one team" effort as it strives to emerge as the fastest growing pharma multinational in the country by 2020.
      PubDate: Thu, 28 Apr 2016 20:25:02 -040
  • China Fast-Tracks Multiple HCV Drugs With Access In Mind
    • Abstract: All eyes on a list of selected oral hepatitis C drugs that are expected to win out in China's notoriously lengthy approval battle, amid a potentially huge opening as Chinese HCV patients switch from interferon to all oral therapies.
      PubDate: Thu, 28 Apr 2016 02:20:01 -040
  • Japan Policy Threats Worry Lilly
    • Abstract: While Lilly's business in Japan grew strongly last year, it seems that concerns over possible policy changes in this key market have permeated up to the highest levels in the US company.
      PubDate: Thu, 28 Apr 2016 01:35:00 -040
  • India Compulsory Licensing: What USTR Hearing Transcripts Say
    • Abstract: Private assurances or not, the prickly debate around the use of compulsory licenses in India appears to have an ongoing subtext going by the transcript of statements by the US-India Business Council (USIBC) before the United States Trade Representative (USTR) at the 2016 Special 301 review public hearing.
      PubDate: Wed, 27 Apr 2016 20:55:01 -040
  • China A Key Driver Of Roche’s International Growth
    • Abstract: China market remains strong in sales of both pharma and diagnostics for Roche under expectation, with strategic approval and additional reimbursement of several oncology products in the country. During the most recent trip to Shanghai, the group’s chairman expressed the hope to deepen the collaboration with the locals.
      PubDate: Wed, 27 Apr 2016 01:10:01 -040
  • Big Pharma's Next Partner In China: Diagnostics
    • Abstract: China offers a fertile ground for combing pharma with diagnostics as it looks to cut cost and improve healthcare results, but a lack of quality and core technologies will mean many diagnostic startups will be forced out in the next wave of consolidation. Pharmas will have to partner selectively and navigate carefully, top executives say in a recent forum.
      PubDate: Tue, 26 Apr 2016 21:25:00 -040
  • Erbitux TAILOR-Made For China First-Line mCRC Market, But Brand
           Recognition Merck’s Real Goal'
    • Abstract: Merck's plans to penetrate the Chinese market further with its anti-EGFR cancer therapy Erbitux have received a boost with the Phase III TAILOR trial showing significant benefits when used first-line in metastatic colorectal cancer in this population.
      PubDate: Tue, 26 Apr 2016 20:55:01 -040
  • Generics And Price Cuts Hit Novartis’s Japan, Emerging Market Sales
    • Abstract: Novartis, whose first quarter pharmaceuticals performance was weighed by Gleevec patent expiries, also suffered from weak sales in Japan and some emerging markets mainly due to impact from generics and price reductions.
      PubDate: Tue, 26 Apr 2016 02:55:01 -040
  • Japan Venture Taps ‘Deep Learning’ To Improve Drug Discovery
    • Abstract: The Japanese peptide venture Interprotein is tapping into artificial intelligence technology with the hope of improving the efficiency and accuracy of its drug discovery efforts.
      PubDate: Tue, 26 Apr 2016 01:40:01 -040
  • Foreign Regulators Rap More Indian Firms Over Data Integrity
    • Abstract: Three more Indian pharmaceutical players have been pulled up by overseas regulators over data integrity issues in another blow to the reputation of the flagship industry.
      PubDate: Mon, 25 Apr 2016 21:05:00 -040
  • Merck KGaA Offering Broad Expertise To Nurture China Start-Ups
    • Abstract: Merck, the German health care and life sciences group, is tapping into China’s burgeoning biotech start-up community through a new grant program under which it is offering financial aid and broad technology support and hopes to help advance novel life-saving therapeutics.
      PubDate: Mon, 25 Apr 2016 03:05:00 -040
  • Tresiba Solid As Novo Nordisk Plots Japan Growth
    • Abstract: Novo Nordisk has had its best year ever in sales terms in Japan, where its subsidiary is benefiting mainly from the strong performance of basal insulin preparation Tresiba.
      PubDate: Mon, 25 Apr 2016 02:30:01 -040
  • BioLeaders Edging Ahead In Dysplasia Therapeutics
    • Abstract: South Korea’s BioLeaders is making solid progress with its pipeline projects for dysplasia, preparing to begin a global Phase III trial with an oral immunotherapy, and adding a new domestic partner to a 2013 global licensing deal for an oral therapeutic vaccine.
      PubDate: Sun, 24 Apr 2016 22:40:01 -040
  • India’s Affordable Medicines Under Threat In Asian RCEP Talks'
    • Abstract: India needs to take a strong stand in Asian free trade negotiations against calls for tougher intellectual property rules that could harm access to affordable medicines for millions of patients around the globe, says Médecins Sans Frontières.
      PubDate: Thu, 21 Apr 2016 22:30:02 -040
  • Bring On Real Growth! Abbott CEO Brushes Off Price Pressures
    • Abstract: Focus less on price increases and more on becoming competitive to achieve real growth in the emerging markets, which Abbott CEO Miles White says remain attractive despite the general slowdown.
      PubDate: Thu, 21 Apr 2016 22:05:02 -040
  • Licenses Clear Path For Daclatasvir In Asia/Africa HCV/HIV Program
    • Abstract: The first supplies of daclatasvir for use in a new US-coordinated program aimed at improving drug access for patients co-infected with HIV/HCV in Asian and African countries will reach first recipients shortly.
      PubDate: Thu, 21 Apr 2016 21:30:01 -040
  • US Foreign Bribery Investigations Ramp Up, With 'Carrot' For Cooperation
    • Abstract: Pilot program from the US Department of Justice reduces fines for companies that voluntarily disclose misconduct; focus of investigations is broadening from sales to suppliers.
      PubDate: Wed, 20 Apr 2016 21:45:01 -040
  • 1Q Preview: Japan Policy Worries, Indian Mixed Bag
    • Abstract: As major companies start to release their quarterly results over the next few weeks, PharmAsia News takes a market-by-market look at some of the key expectations, challenges and policy factors likely to have the biggest influence on Asia’s major corporate players.
      PubDate: Wed, 20 Apr 2016 20:55:01 -040
  • 1Q Preview: Mixed China, Korea Outlook As Policies, Economics Bite
    • Abstract: As major companies start to release their quarterly results over the next few weeks, PharmAsia News takes a market-by-market look at some of the key expectations, challenges and policy factors likely to have the biggest influence on Asia’s major corporate players.
      PubDate: Wed, 20 Apr 2016 20:25:01 -040
  • Turkey Regulatory Update: New Vaccine Policy, Drug Protocol
    • Abstract: The need for parental consent for some childhood vaccinations has been waived under a new law, the government is offering an attractive purchasing guarantee to medtech companies investing in local production, and pharmacists have signed a new protocol.
      PubDate: Wed, 20 Apr 2016 04:10:01 -040
  • WHO Raps India’s ‘Low Level’ Public Health Care
    • Abstract: The World Health Organization's new India head says the country must hike public health care spending and stop Indians falling into poverty due to medical expenses. The call coincides with new government figures highlighting the lack of medical care access in the country.
      PubDate: Wed, 20 Apr 2016 03:35:01 -040
  • Biostar, Kangstem Expand Stem Cell Therapy Pipelines Into AD, Psoriasis
    • Abstract: Biostar Group and Kangstem Biotech are expanding their stem cell therapy pipelines via additional indications and a joint development deal, marking a further expansion of South Korea’s activities in the field into the new areas of Alzheimer’s and psoriasis.
      PubDate: Tue, 19 Apr 2016 23:30:01 -040
  • PROFILE: Bangladesh Market On Uptrend Amid Hep C Buildup
    • Abstract: Half a dozen corporate players, community-based diagnosis and patient support efforts, and an inflow of treatment seekers from abroad keen to access cut-price drugs in the country – this probably summarizes the current state of play in Bangladesh's market for sofosbuvir.
      PubDate: Tue, 19 Apr 2016 02:40:02 -040
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015